| Biomarker ID | 1984 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation status of RASGRF2 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethlated in Recurrent prostate cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Recurrent prostate cancer Vs nonrecurrent cancer |
| Type of Biomarker | Prognostic |
| Cohort | Recurrence (n = 123) versus nonrecurrence (n = 75) |
| Senstivity | Training: 69.4 (59.3–78.3); validation:75.7 (50.9–91.3) |
| Specificity | Training: 71.7 (58.6–82.5); validation:55.2 (31.5–76.9) |
| AUC | Training: 0.763; validation: 0.68 |
| Accuracy | NA |
| Level Of Significance | <0.0001 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | RASGRF2 |